Charles River Laboratories International, Inc. reports results for the quarter ended June 30 - Earnings Summary

Charles River Laboratories International

05/08/2026 14:31

Charles River Laboratories International, Inc. CRL.N reported quarterly adjusted earnings of $3.02​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of $3.12.  The mean expectation of twelve analysts for the quarter was for earnings of $2.74 per share. Wall Street expected results to range from $2.68  to $2.91 per share.
Revenue fell 2.7% to $1.00 billion from a year ago; analysts expected $975.69 million. 
Charles River Laboratories International, Inc.'s reported EPS for the quarter was a loss of 3 cents​.
The company reported a quarterly loss of $1.48 million.
Charles River Laboratories International, Inc. shares had risen by 3.2% this quarter and gained 17.4% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 1.3% in the last three months.​ 
In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Charles River Laboratories International, Inc. is $235.00, about 0.4% above its last closing price of $234.12
This summary was machine generated from LSEG data August 5 at 01:30 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
2.74
3.02
Beat
Mar. 31 2026 
1.94
2.06
Beat
Dec. 31 2025 
2.34
2.39
Beat
Sep. 30 2025 
2.34
2.43
Beat